Literature DB >> 15701287

Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case study.

Alfredo D Voloschin1, David N Louis, Garth R Cosgrove, Tracy T Batchelor.   

Abstract

A 38-year-old woman presented with an infiltrative tumor of the right frontal lobe and genu of the corpus callosum that was deemed only partially resectable. A stereotactic biopsy was performed, which revealed a right frontal oligoastrocytoma that had some anaplastic features as well as allelic loss of chromosome arms 1p and 19q. The patient was treated with temozolomide for 24 months. The partial response of the tumor to chemotherapy rendered the lesion amenable to gross total resection, which was performed subsequently. The patient remains alive and well without evidence of recurrence 7 months after resection and 48 months after initial diagnosis. Thus, preoperative chemotherapy decreased tumor mass to a degree that subsequently enabled a gross total resection. This treatment strategy, although common in the treatment of other solid tumors, is rarely utilized in adult neuro-oncology and raises another potential role for chromosome testing in oligodendroglial tumor management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701287      PMCID: PMC1871619          DOI: 10.1215/S1152851704000560

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  17 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma".

Authors:  Hikaru Sasaki; Magdalena C Zlatescu; Rebecca A Betensky; Loki B Johnk; Andrea N Cutone; J Gregory Cairncross; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2002-01       Impact factor: 3.685

3.  Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.

Authors:  Ali Chahlavi; Andrew Kanner; David Peereboom; Susan M Staugaitis; Paul Elson; Gene Barnett
Journal:  J Neurooncol       Date:  2003-02       Impact factor: 4.130

Review 4.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Authors:  Martin van den Bent; Olivier-Louis Chinot; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

5.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Authors:  M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  Complete surgical resection in children with low-grade astrocytomas after neoadjuvant chemotherapy.

Authors:  Elvis Terci Valera; Luciano Neder Serafini; Hélio Rubens Machado; Luiz Gonzaga Tone
Journal:  Childs Nerv Syst       Date:  2003-02-04       Impact factor: 1.475

Review 7.  Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.

Authors:  Guido Reifenberger; David N Louis
Journal:  J Neuropathol Exp Neurol       Date:  2003-02       Impact factor: 3.685

8.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Authors:  J G Cairncross; K Ueki; M C Zlatescu; D K Lisle; D M Finkelstein; R R Hammond; J S Silver; P C Stark; D R Macdonald; Y Ino; D A Ramsay; D N Louis
Journal:  J Natl Cancer Inst       Date:  1998-10-07       Impact factor: 13.506

9.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

Authors:  M J van den Bent; M J B Taphoorn; A A Brandes; J Menten; R Stupp; M Frenay; O Chinot; J M Kros; C C D van der Rijt; Ch J Vecht; A Allgeier; T Gorlia
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

10.  Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy.

Authors:  Robert C Shamberger; Michael P LaQuaglia; Mark C Gebhardt; James R Neff; Nancy J Tarbell; Karen C Marcus; Scott L Sailer; Richard B Womer; James S Miser; Paul S Dickman; Elizabeth J Perlman; Meenakshi Devidas; Stephen B Linda; Mark D Krailo; Holcombe E Grier; Linda Granowetter
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

View more
  5 in total

1.  Upfront chemotherapy and subsequent resection for molecularly defined gliomas.

Authors:  Hikaru Sasaki; Yuichi Hirose; Takahito Yazaki; Yohei Kitamura; Makoto Katayama; Tokuhiro Kimura; Hirokazu Fujiwara; Masahiro Toda; Takayuki Ohira; Kazunari Yoshida
Journal:  J Neurooncol       Date:  2015-05-26       Impact factor: 4.130

2.  Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.

Authors:  Jasmin Jo; Brian Williams; Mark Smolkin; Max Wintermark; Mark E Shaffrey; M Beatriz Lopes; David Schiff
Journal:  J Neurooncol       Date:  2014-07-20       Impact factor: 4.130

3.  Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma.

Authors:  Hugues Duffau; Luc Taillandier; Laurent Capelle
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

4.  Chemotherapy alleviates subacute recurrent glioma-associated refractory cerebral edema by downregulating vascular endothelial growth factor.

Authors:  Hai-long Li; Xiang-li Cui; Jian-ning Zhang; Song Lin
Journal:  Med Oncol       Date:  2014-05-27       Impact factor: 3.064

Review 5.  Gliomas Infiltrating the Corpus Callosum: A Systematic Review of the Literature.

Authors:  Paolo Palmisciano; Gianluca Ferini; Gina Watanabe; Christian Ogasawara; Emal Lesha; Othman Bin-Alamer; Giuseppe E Umana; Kenny Yu; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.